PTSD: A Condition That Resists Treatment

Post-traumatic stress disorder (PTSD) affects approximately 6% of the U.S. population at some point in their lives (National Center for PTSD). First-line treatments include trauma-focused psychotherapies — Cognitive Processing Therapy (CPT), Prolonged Exposure (PE), and Eye Movement Desensitization and Reprocessing (EMDR) — along with FDA-approved medications sertraline (Zoloft) and paroxetine (Paxil).

However, approximately 40–60% of patients do not achieve adequate response to first-line treatments (Steenkamp et al., 2015). This treatment gap has driven interest in novel approaches, including ketamine.

How Ketamine May Help PTSD

The proposed mechanisms by which ketamine may benefit PTSD differ somewhat from its antidepressant mechanisms:

  • Fear memory reconsolidation: NMDA receptors play a critical role in memory reconsolidation. Ketamine may disrupt the reconsolidation of traumatic memories, reducing their emotional intensity when they are subsequently recalled (Bhatt et al., 2017)
  • Default mode network modulation: PTSD is associated with hyperactivity in brain regions involved in threat detection and self-referential processing. Ketamine may temporarily modulate these circuits, providing a window for therapeutic change
  • Rapid symptom relief: By rapidly reducing comorbid depression, anxiety, and suicidal ideation, ketamine may enable patients to more effectively engage in trauma-focused psychotherapy
  • Neuroplasticity enhancement: Ketamine-induced synaptogenesis may help the brain form new associations that overwrite maladaptive trauma responses

Clinical Evidence

Feder et al. (2014) — First RCT

The first randomized controlled trial of ketamine for PTSD, published in JAMA Psychiatry, administered a single IV ketamine infusion (0.5 mg/kg) to 41 patients with chronic PTSD. Ketamine produced rapid and significant reductions in PTSD symptom severity compared to midazolam control within 24 hours. Effects began to wane over the following week.

Feder et al. (2021) — Repeated Infusions

A follow-up study published in the American Journal of Psychiatry examined repeated IV ketamine infusions (6 infusions over 2 weeks) in 30 patients with chronic PTSD. The ketamine group showed significantly greater improvement than midazolam control on CAPS-5 scores, with a large effect size. Notably, improvements persisted for approximately 2 weeks after the final infusion.

Ketamine-Assisted Psychotherapy for PTSD

An emerging approach combines ketamine with structured psychotherapy sessions. The rationale is that ketamine's neuroplasticity-promoting effects may create an optimal window — sometimes called a "critical period" — during which psychotherapy is more effective. Preliminary studies suggest this combination may produce more durable benefits than either treatment alone, though larger controlled trials are needed.

How Ketamine Fits with Standard PTSD Care

Ketamine is not a replacement for established PTSD treatments. Current clinical practice positions it as:

  • An option for patients who have not responded to first-line psychotherapy and medications
  • A potential bridge therapy — providing rapid relief while longer-term treatments take effect
  • A possible adjunct to trauma-focused psychotherapy, enhancing engagement and response

Important Considerations

PTSD treatment with ketamine requires careful clinical judgment. The dissociative properties of ketamine may be distressing for some trauma survivors. Experienced providers typically:

  • Screen patients carefully for dissociative disorders before treatment
  • Prepare patients for the dissociative experience with education and grounding techniques
  • Coordinate closely with the patient's existing mental health provider
  • Monitor for re-traumatization or symptom exacerbation

This article is for informational purposes only and does not constitute medical advice. PTSD treatment decisions should be made with a qualified mental health provider.